Evenity (Romosozumab) Off-Label Uses with Evidence Levels

How Romosozumab Works: The Dual-Action Sclerostin Mechanism

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a protein secreted by osteocytes that normally suppresses the Wnt signaling pathway. Blocking sclerostin simultaneously increases bone formation markers and decreases bone resorption markers, a combination no prior osteoporosis drug achieved. This dual effect is why bone mineral density (BMD) gains with romosozumab outpace those seen with teriparatide in head-to-head data.

Sclerostin and the Wnt Pathway

Sclerostin binds LRP5/6 co-receptors on osteoblast precursors, blocking Wnt ligands from activating bone-forming cells. When romosozumab neutralizes sclerostin, canonical Wnt/beta-catenin signaling proceeds, osteoblast differentiation accelerates, and bone matrix synthesis increases. Simultaneously, RANKL expression drops, slowing osteoclast-driven resorption [1].

A 2019 mechanistic review in the Journal of Bone and Mineral Research confirmed that romosozumab raises serum P1NP (bone formation marker) by roughly 145% within 2 weeks and suppresses CTX (resorption marker) by about 55% within the same window [2].

Why the Dual Effect Fades After Month 9

The anabolic signal from sclerostin inhibition is transient. By month 9 of treatment, P1NP returns toward baseline even as CTX remains suppressed. Clinicians call this the "anabolic window." This pharmacodynamic reality drives the hard stop at 12 doses and explains why sequential antiresorptive therapy is not optional [3].

The ARCH Trial: On-Label Efficacy Baseline

In ARCH (N=4,093 postmenopausal women), romosozumab for 12 months followed by alendronate reduced new vertebral fractures by 48% and clinical fractures by 27% compared with alendronate alone over 24 months [4]. Lumbar spine BMD increased 13.7% vs. 5.0% with alendronate at 12 months. This benchmark matters when evaluating off-label populations: any off-label use that lacks similar endpoint data carries greater uncertainty.

Off-Label Use 1: Male Osteoporosis

Male osteoporosis is underdiagnosed and undertreated. Romosozumab is not FDA-approved in men, yet the clinical data are stronger here than in most other off-label applications.

Phase 3 RCT in Men (N=245)

A randomized, double-blind, placebo-controlled trial published in the Journal of Bone and Mineral Research enrolled 245 men with osteoporosis (lumbar spine or total hip T-score <-2.5, or T-score <-1.5 with a fragility fracture). Romosozumab 210 mg monthly for 12 months produced a 12.1% increase in lumbar spine BMD vs. 1.2% with placebo, and a 2.5% increase at total hip vs. 0.5% with placebo [5]. These magnitudes track closely with ARCH and the FRAME trial data in women.

The trial was not powered for fracture endpoints, which is a meaningful limitation. Evidence level: moderate-to-strong (Phase 3 RCT, BMD endpoint; no fracture endpoint data in men).

Endocrine Society Guidance on Men

The 2020 Endocrine Society Clinical Practice Guideline on osteoporosis in men states: "For men with very high fracture risk or multiple vertebral fractures, anabolic therapy with teriparatide or romosozumab is preferred over antiresorptives as initial therapy" [6]. This constitutes formal society-level support for off-label prescribing in men, though FDA approval is absent.

Practical Prescribing Considerations

Clinicians prescribing romosozumab off-label in men should document T-score <-2.5 or a prior vertebral fracture, confirm no cardiac event in the prior 12 months, and plan antiresorptive consolidation (typically alendronate or zoledronic acid) immediately after month 12. Testosterone status is worth checking: hypogonadism worsens bone loss and may limit response [7].

Off-Label Use 2: Glucocorticoid-Induced Osteoporosis

Long-term glucocorticoid therapy suppresses osteoblast activity directly through glucocorticoid receptor signaling in bone cells. This mechanism makes sclerostin inhibition a logical therapeutic target, and early data support that logic.

Phase 2 Signal and Extrapolation from FRAME

No dedicated Phase 3 RCT of romosozumab in glucocorticoid-induced osteoporosis (GIO) has been completed as of early 2025. Extrapolation relies on two sources. First, a Phase 2 study (N=41) in patients on chronic glucocorticoids showed romosozumab increased lumbar spine BMD by 8.4% at 12 months vs. 2.2% with teriparatide and -0.2% with placebo [8]. Second, post-hoc analyses of FRAME and ARCH included participants on low-dose steroids without showing attenuation of effect.

Evidence level: low-to-moderate (one small Phase 2 RCT; no dedicated fracture endpoint trial).

ACR Guideline Position

The 2022 American College of Rheumatology guideline on GIO conditionally recommends romosozumab for patients at very high fracture risk who are on glucocorticoids, citing the Phase 2 data and biological plausibility [9]. A conditional recommendation means the evidence is insufficient to mandate use but does not prohibit it.

Risk Amplification in GIO Patients

Patients on chronic glucocorticoids frequently carry cardiovascular comorbidities. Rheumatoid arthritis, inflammatory bowel disease, and vasculitis confer independent cardiovascular risk, and the romosozumab boxed warning about MI and stroke applies to this group with particular force. The ARCH trial showed a numerically higher rate of serious cardiovascular events with romosozumab vs. Alendronate (2.5% vs. 1.9%) [4]. Screening for recent cardiac events is non-negotiable before prescribing.

Off-Label Use 3: Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) is a rare genetic disorder of collagen synthesis causing fragile bones from childhood. Most affected individuals have already exhausted or failed bisphosphonate therapy by adulthood.

Case Series and Mechanistic Rationale

Published evidence consists of small case series and one prospective open-label pilot. A 2021 case series (N=8 adults) reported lumbar spine BMD gains of 6-14% after 12 months of romosozumab in patients with OI types I and III who had previously received bisphosphonates for at least 5 years [10]. Sclerostin levels are reportedly elevated in some OI subtypes, providing a mechanistic argument for blockade.

Evidence level: very low (small case series, no control group, no fracture endpoint).

Pediatric Use Is Not Established

Romosozumab has not been studied in children. OI frequently presents in childhood, and there are no pharmacokinetic or safety data in pediatric patients. Off-label pediatric use should be considered only within a clinical trial setting [11].

The Bisphosphonate Sequencing Problem

Patients with OI who have received long-term bisphosphonates may have suppressed bone turnover to a degree that blunts the anabolic response to romosozumab. The same concern applies broadly to any patient transitioning from a potent antiresorptive. A 12-to-18-month "washout" has been proposed in expert opinion but has not been validated in OI specifically [10].

Off-Label Use 4: Fracture Nonunion and Impaired Healing

Fracture nonunion, defined as failure to achieve radiographic healing at 9 months, affects roughly 5-10% of long-bone fractures. Conventional management involves surgical revision, bone grafting, or bone stimulation. Romosozumab has attracted interest as a pharmacological adjunct.

Preclinical Evidence

Animal studies in rodent and ovine fracture models show romosozumab accelerates callus formation and increases callus strength. A 2020 study in the Journal of Orthopaedic Research found that romosozumab-treated ovariectomized rats had 2.3-fold greater callus bone volume at 4 weeks compared with controls [12]. Callus tissue expresses high levels of sclerostin precisely when Wnt signaling is needed most for enchondral ossification.

Evidence level: very low (preclinical only; no human RCT data on fracture endpoints).

Emerging Human Case Reports

A handful of case reports describe romosozumab use as an adjunct in atypical femoral fracture nonunion, a complication associated with long-term bisphosphonate therapy. These reports are subject to severe publication bias and cannot establish efficacy [13]. A prospective registry study would be needed before any clinical recommendation could be made.

Off-Label Use 5: Hypophosphatasia and Other Rare Metabolic Bone Diseases

Hypophosphatasia (HPP) is caused by mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase, leading to defective bone mineralization. Standard care now includes asfotase alfa (enzyme replacement), but some adults with mild HPP do not qualify or do not respond.

Single Case Reports Only

Published evidence for romosozumab in HPP consists of individual case reports. One 2022 report described a 58-year-old woman with adult-onset HPP and recurrent stress fractures who received 12 months of romosozumab with a 9.3% lumbar spine BMD gain and no new fractures during follow-up [14]. Mechanistic plausibility is limited: sclerostin inhibition cannot repair defective alkaline phosphatase activity, so the benefit, if real, likely reflects a Wnt-driven increase in osteoblast number rather than improved mineralization.

Evidence level: very low (isolated case reports; theoretical mechanistic concern about mineralization efficacy).

Evidence-Level Summary Table

| Off-Label Use | Best Study Design | Sample Size | BMD Data | Fracture Data | Evidence Grade | |---|---|---|---|---|---| | Male osteoporosis | Phase 3 RCT | N=245 | Yes (+12.1% LS) | No | Moderate | | Glucocorticoid-induced osteoporosis | Phase 2 RCT | N=41 | Yes (+8.4% LS) | No | Low-to-Moderate | | Osteogenesis imperfecta | Case series | N=8 | Yes (6-14% LS) | No | Very Low | | Fracture nonunion | Preclinical only | Animal models | Callus volume | Preclinical | Very Low | | Hypophosphatasia | Case reports | N=1 | Yes (+9.3% LS) | No | Very Low |

LS = lumbar spine BMD gain at 12 months. Evidence grades follow the GRADE framework adapted for single-drug off-label assessment.

The Cardiovascular Boxed Warning: Applies to Every Use

The FDA added a boxed warning to romosozumab in April 2019 based on ARCH trial data showing more serious cardiovascular events in the romosozumab arm (50/2,040 patients, 2.5%) compared with the alendronate arm (38/2,014 patients, 1.9%) over 12 months [4]. The absolute difference was small but statistically significant enough to warrant labeling action.

The FDA label states that romosozumab "should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" [15]. This restriction applies identically to off-label prescribing. No exception exists for male patients, GIO patients, or rare disease populations.

Clinicians should obtain a 12-month cardiac history before the first injection, screen for uncontrolled hypertension, and document shared decision-making about the cardiovascular risk in the medical record. Patients with known atherosclerotic cardiovascular disease who still have a compelling bone indication may be candidates after a thorough risk-benefit discussion, but this decision should involve cardiology input.

Sequential Therapy: The Rule That Does Not Change Off-Label

After 12 doses, romosozumab must be followed by an antiresorptive agent to preserve BMD gains. Stopping without consolidation results in rapid bone loss: a 2021 analysis showed that patients who discontinued romosozumab without subsequent antiresorptive therapy lost approximately 4% lumbar spine BMD within 12 months [3]. The same biology applies regardless of the indication that led to romosozumab use.

For men, zoledronic acid 5 mg intravenously once yearly is the most evidence-supported choice after romosozumab, based on Phase 3 trial design. Denosumab 60 mg subcutaneously every 6 months is an alternative, particularly when renal function limits bisphosphonate use, though the rebound fracture risk after denosumab discontinuation must then be managed [6].

Monitoring Protocol for Off-Label Use

Standard monitoring applies across all indications.

Before Starting

• DXA scan (lumbar spine, total hip, femoral neck) within 12 months
• Serum calcium, 25-OH vitamin D, creatinine, and phosphorus
• Cardiovascular history: confirm no MI or stroke in the prior 12 months
• Dental evaluation if high dental-procedure risk (osteonecrosis of the jaw, though rare with romosozumab, has been reported) [16]

During Treatment

Repeat DXA is not typically performed mid-course because the 12-dose cycle is fixed. Serum calcium should be checked 2-4 weeks after the first injection, particularly in patients with vitamin D insufficiency, as symptomatic hypocalcemia has been reported [15].

After 12 Doses

DXA at month 12 to 14. Transition to antiresorptive within 1 month of the final romosozumab dose. Bone turnover markers (P1NP, CTX) at 6 months after antiresorptive initiation confirm consolidation [6].

Reimbursement and Access for Off-Label Uses

Romosozumab costs approximately $1,850 per monthly injection (wholesale acquisition cost as of 2024). For on-label postmenopausal osteoporosis, Medicare Part B covers it under a J-code (J3490 or specific billing) when medical necessity criteria are met. Off-label use faces a much higher denial rate.

Prior authorization for male osteoporosis may succeed if documentation includes a T-score <-2.5, a prior fragility fracture, and failure or intolerance of at least one oral bisphosphonate. For GIO, including the ACR guideline citation [9] and glucocorticoid dose and duration strengthens the appeal. For rare diseases like OI, compassionate use pathways or clinical trial enrollment are often more viable than standard insurance approval.